STOCK TITAN
  1. Home
  2. SEC Filings
  3. TXG
  4. [8-K] 10x Genomics, Inc. Reports Material Event

10x Genomics raises 2026 revenue outlook to $625M–$635M

10x Genomics began global commercial shipments of Atera and introduced Sentira, a cloud analysis platform.

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
8-K

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported third-quarter 2026 revenue of $150.7 million, up 1% from $149.0 million a year earlier. Gross margin was 75%, versus 67%; the increase primarily reflected lower inventory write-downs and changes in product mix. Operating expenses were $129.0 million, down 3% from $132.5 million, primarily due to lower personnel and lab equipment expenses, partly offset by higher litigation expenses. Operating loss narrowed to $16.1 million from $32.2 million, and net loss narrowed to $19.4 million from $27.5 million. Cash, cash equivalents and marketable securities totaled $575.7 million as of September 30, 2026.

Management raised full-year 2026 revenue guidance to $625 million to $635 million, from $610 million to $630 million. Excluding non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, the updated range represents 4% to 6% growth over full-year 2025. For the first nine months of 2026, revenue was $452.5 million versus $476.8 million, and net loss was $50.8 million versus $27.3 million.

3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance rose to $625 million to $635 million.
  • Moderate pointThird-quarter net loss narrowed to $19.4 million from $27.5 million.
  • Moderate pointGross margin increased to 75% from 67% year over year.

Negative

  • Moderate pointNine-month revenue was $452.5 million, versus $476.8 million a year earlier.
  • Moderate pointNine-month net loss widened to $50.8 million from $27.3 million.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $150.7 million Third quarter 2026; 1% increase from the corresponding 2025 period
Gross margin 75% Third quarter 2026; compared with 67% in the corresponding 2025 period
Operating loss $16.1 million Third quarter 2026; compared with $32.2 million in the corresponding 2025 period
Net loss $19.4 million Third quarter 2026; compared with $27.5 million in the corresponding 2025 period
Cash, cash equivalents and marketable securities $575.7 million As of September 30, 2026
2026 revenue guidance $625 million to $635 million Raised from the previous range of $610 million to $630 million
Nine-month revenue $452.5 million First nine months of 2026; compared with $476.8 million in 2025
Nine-month net loss $50.8 million First nine months of 2026; compared with $27.3 million in 2025
Gross margin financial
"Gross margin was 75% for the third quarter of 2026"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
License and royalty revenue financial
"License and royalty revenue related to patent litigation settlements"
Marketable securities financial
"Cash and cash equivalents and marketable securities"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
Weighted-average shares financial
"Weighted-average shares used to compute net loss per share"
Weighted-average shares is the average number of a company’s outstanding shares calculated over a reporting period, adjusted for any stock issuances, repurchases, or splits during that time. Investors use it to fairly compare earnings per share and other per-share metrics, because it smooths out changes in the share count the way an average speed reflects trips of different lengths rather than a single snapshot.
Contingent consideration financial
"Contingent consideration, current"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
Revenue $150.7 million 1% increase from $149.0 million in the corresponding 2025 period
Gross margin 75% Compared with 67% in the corresponding 2025 period
Operating expenses $129.0 million 3% decrease from $132.5 million in the corresponding 2025 period
Operating loss $16.1 million Compared with $32.2 million in the corresponding 2025 period
Net loss $19.4 million Compared with $27.5 million in the corresponding 2025 period
Guidance

Raised full-year 2026 revenue guidance to $625 million to $635 million from $610 million to $630 million; excluding non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over full-year 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was TXG's revenue in the third quarter of 2026?
TXG reported third-quarter 2026 revenue of $150.7 million, up 1% from $149.0 million in the third quarter of 2025. Gross margin was 75%, versus 67%, while operating loss narrowed to $16.1 million from $32.2 million and net loss narrowed to $19.4 million from $27.5 million.

What is 10x Genomics' 2026 revenue guidance?
10x Genomics raised its full-year 2026 revenue guidance to $625 million to $635 million, from $610 million to $630 million. Excluding non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, the range represents 4% to 6% growth over full-year 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000177078700017707872026-11-052026-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2026

Logo-10x.jpg
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39035
45-5614458
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Class A common stock, par value $0.00001 per share
TXG
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.
Description of Exhibits
99.1
Press Release dated November 5, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By:
/s/ Randy Wu
Name:
Randy Wu
Title:
General Counsel and Secretary
Date: November 5, 2026


Exhibit 99.1
a10x_logoxhorizontalxfullc.jpg
10x Genomics Reports Third Quarter 2026 Financial Results
PLEASANTON, Calif. November 5, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.
Recent Updates
•Revenue was $150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025.
•Began global commercial shipments of Atera, with extraordinary early demand translating into ambitious new research programs spanning discovery, translational and biopharma research.
•Introduced Sentira, a cloud analysis platform to help customers turn complex biological datasets into insights, powered by NVIDIA accelerated computing for spatial data processing and Anthropic’s Claude for agentic AI analysis of single cell data.
“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”
Third Quarter 2026 Financial Results
Revenue was $150.7 million for the third quarter of 2026, as compared to $149.0 million for the corresponding period of 2025. Revenue increased 1% over the corresponding period of 2025.
Gross margin was 75% for the third quarter of 2026, as compared to 67% for the corresponding prior year period. The increase in gross margin was primarily due to lower inventory write-downs and changes in product mix.
Operating expenses were $129.0 million for the third quarter of 2026, a 3% decrease from $132.5 million for the corresponding prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses.
Operating loss was $16.1 million for the third quarter of 2026, as compared to operating loss of $32.2 million for the corresponding prior year period.
Net loss was $19.4 million for the third quarter of 2026, as compared to net loss of $27.5 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026.
2026 Financial Guidance
10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million, versus the previous range of $610 million to $630 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over full year 2025.

Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the third quarter 2026 financial results, business developments and outlook after market close on Thursday, November 5, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
1
a10x_logoxhorizontalxfullc.jpg
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," “outlook,” "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s products, services, business strategy, collaborations and opportunities; the commercial launch of, demand for and customer adoption of Atera; the capabilities, availability and expected benefits of Sentira, including its use of third-party accelerated computing and artificial intelligence technologies; the role of artificial intelligence in advancing biological research and 10x Genomics, Inc.’s ability to benefit from that trend; continued demand for consumables; and 10x Genomics, Inc.’s financial performance and results of operations, including expectations regarding revenue, revenue growth and guidance. These statements are based on management's current expectations, forecasts, beliefs, estimates, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the U.S. Securities and Exchange Commission (“SEC”), and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
a10x_logoxhorizontalxfullc.jpg
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Products and services revenue$150,210 $148,019 $449,200 $430,999 
License and royalty revenue457 983 3,346 45,794 
Revenue (1)
150,667 149,002 452,546 476,793 
Cost of products and services revenue (2)
37,740 48,695 120,944 145,957 
Gross profit112,927 100,307 331,602 330,836 
Operating expenses:
Research and development (2)
52,929 57,194 166,567 182,663 
Selling, general and administrative (2)
76,055 75,355 221,093 239,517 
Gain on settlement— — (3,400)(49,900)
Total operating expenses128,984 132,549 384,260 372,280 
Loss from operations(16,057)(32,242)(52,658)(41,444)
Other income (expense):
Interest income5,018 5,199 14,829 13,156 
Interest expense— 3 — — 
Other income (expense), net(7,437)(1,165)(12,139)3,574 
Total other income (expense)(2,419)4,037 2,690 16,730 
Loss before provision for income taxes(18,476)(28,205)(49,968)(24,714)
Provision for (benefit from) income taxes949 (733)858 2,578 
Net loss$(19,425)$(27,472)$(50,826)$(27,292)
Net loss per share, basic and diluted$(0.15)$(0.22)$(0.39)$(0.22)
Weighted-average shares used to compute net loss per share, basic and diluted130,805,838 125,502,291 129,570,736 123,965,205 
__________________________
3
a10x_logoxhorizontalxfullc.jpg
(1)    The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company’s Visium, Xenium and Atera products:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Instruments
Single Cell$3,782 $4,927 $12,092 $16,567 
Spatial3,076 7,072 13,689 24,744 
Total instruments revenue6,858 11,999 25,781 41,311 
Consumables
Single Cell93,139 92,519 270,484 262,416 
Spatial41,188 35,373 124,396 103,017 
Total consumables revenue134,327 127,892 394,880 365,433 
Services9,025 8,128 28,539 24,255 
Products and services revenue150,210 148,019 449,200 430,999 
License and royalty revenue457 983 3,346 45,794 
Total revenue$150,667 $149,002 $452,546 $476,793 
(1)    The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Americas
United States*
$82,093 $77,246 $240,895 $267,555 
Americas (excluding United States)3,849 2,625 10,172 9,044 
Total Americas85,942 79,871 251,067 276,599 
Europe, Middle East and Africa38,753 41,624 115,577 108,253 
Asia-Pacific
China15,216 15,189 46,021 55,242 
Asia-Pacific (excluding China)10,756 12,318 39,881 36,699 
Total Asia-Pacific25,972 27,507 85,902 91,941 
Total revenue$150,667 $149,002 $452,546 $476,793 
* Includes license and royalty revenue.
(2)    Includes stock-based compensation expense as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)
2026202520262025
Cost of revenue$2,157 $2,011 $5,911 $6,481 
Research and development8,940 11,318 30,168 38,037 
Selling, general and administrative11,999 11,935 35,275 39,067 
Total stock-based compensation expense$23,096 $25,264 $71,354 $83,585 
4
a10x_logoxhorizontalxfullc.jpg
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
September 30,
2026		December 31,
2025
Assets
Current assets:
Cash and cash equivalents$526,187 $473,966 
Marketable securities49,493 49,443 
Accounts receivable, net55,701 47,013 
Other receivables3,055 35,480 
Inventory64,629 56,341 
Prepaid expenses and other current assets19,566 22,208 
Total current assets718,631 684,451 
Property and equipment, net210,239 226,711 
Operating lease right-of-use assets54,759 60,450 
Goodwill6,918 4,511 
Intangible assets, net58,663 62,329 
Other noncurrent assets13,919 2,913 
Total assets$1,063,129 $1,041,365 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$21,594 $12,733 
Accrued compensation and related benefits39,657 42,500 
Accrued expenses and other current liabilities32,181 39,971 
Deferred revenue22,956 23,902 
Operating lease liabilities11,946 10,985 
Contingent consideration, current12,036 23,363 
Total current liabilities140,370 153,454 
Contingent consideration, noncurrent5,842 1,237 
Operating lease liabilities, noncurrent63,846 73,376 
Deferred revenue, noncurrent8,530 10,501 
Other noncurrent liabilities6,505 6,471 
Total liabilities225,093 245,039 
Stockholders’ equity:
Preferred stock— — 
Common stock2 2 
Additional paid-in capital2,399,254 2,306,690 
Accumulated deficit(1,561,417)(1,510,591)
Accumulated other comprehensive income197 225 
Total stockholders’ equity838,036 796,326 
Total liabilities and stockholders’ equity$1,063,129 $1,041,365 
5

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents

Keep reading

More on TXG

All TXG news

Trending in the feed

IREN
IREN Reports Q1 FY27 Results Open the live feed